Neeraj Agarwal: Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC prostate cancer
Neeraj Agarwal shared the following on Twitter:
“Just in Nature Medicine: Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC prostate cancer enza + tala vs. enza, rPFS HR 0.44, OS trending strongly HR 0.69, efficacy in multiple HRR gene subsets”
For details click here.
Source: Neeraj Agarwal/Twitter
Neeraj Agarwal is a Professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023